NCT07863869Not yet recruitingPhase 1/2
The QL1706 Combined With Chemotherapy and Either Cetuximab or Bevacizumab in Potentially Resectable Colorectal Cancer Patients With Liver Metastases
A Phase ⅠB/Ⅱ Study of QL1706 Combined With Chemotherapy and Either Cetuximab or Bevacizumab in Potentially Resectable Colorectal Cancer Patients With Liver Metastases
Source: ClinicalTrials.gov · Last updated 19 Oct 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn if QL1706 (Iparomlimab/ Tuvonralimab)+ chemotherapy+ cetuximab/bevacizumab works to treat potentially resectable colorectal cancer patients with liver metastases in adults. It will also learn about the safety of this therapeutic regimen. The main questions it aims to answer are: Does QL1706+ Chemotherapy+ Cetuximab/Bevacizumab improve the 18-month progression free survival (PFS) rate of participants? The study plans to enroll 90-102 patients, who will be divided into 2 arms based on the primary tumor location and genetic status. Arm A: Patients with primary tumors located in the left colorectum and RAS ( Rat Sarcoma Virus ) and BRAF ( V-raf Murine Sarcoma Viral Oncogene Homolog B ) wild-type. Arm B: Patients with primary tumors located in the right colorectum and/or RAS or BRAF mutant The study consists of two phases: phase Ib ( safety run-in phase ) and phase II.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 102 (estimated)
- First submitted
- 31 Mar 2026
- Start date
- Sept 2026
- Primary completion date
- 27 May 2029
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Diseases
- Colorectal cancer
- NCT number
- NCT07863869
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 102
- From Sept 2026 to the primary completion date, 27 May 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous receipt of immune checkpoint inhibitors, including: anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, etc.
- Previous or concurrent other malignant tumors within 5 years;
Other illness
- Active autoimmune diseases requiring systemic treatment occurring within 2 years before enrollment.
- HIV infection, other acquired or congenital immunodeficiency diseases, or a history of organ transplantation or allogeneic bone marrow transplantation (except corneal transplantation).
- Known active pulmonary tuberculosis, radiation pneumonitis, drug-induced pneumonia, or other diseases, symptoms, or signs causing severe impairment of lung function.
Lab values
- Previous receipt of targeted drugs targeting epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), or their receptors (VEGFR), including bevacizumab, cetuximab, panitumumab, aflibercept, regorafenib, anlotinib, etc.
Other
- Definite extrahepatic distant metastatic lesions.
- Unresectable primary tumor.
- Accompanying pleural effusion, pericardial effusion, or ascites that is uncontrollable and requires drainage.
Who the study is looking for
- Has signed a written informed consent form and voluntarily participates in this study;
- Age: 18-75 years old, regardless of gender;
- Histologically or cytologically confirmed colorectal adenocarcinoma with liver metastases, initially unresectable but potentially resectable as assessed by a multidisciplinary team (MDT), without other definite extrahepatic distant metastases;
- No prior systemic treatment;
- Known RAS and BRAF status;
- No contraindications to liver surgery;
- At least one measurable lesion according to RECIST 1.1;
- ECOG performance status: 0-1;
- Expected survival time \> 12 weeks;
- Sufficient organ and bone marrow function.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.